Navidea Biopharmaceuticals (NAVB) 10-Q 16 May 22 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 09, 2022
Document Information [Line Items]
Entity Central Index Key	0000810509
Entity Registrant Name	NAVIDEA BIOPHARMACEUTICALS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-35076
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	31-1080091
Entity Address, Address Line One	4995 Bradenton Avenue, Suite 240
Entity Address, City or Town	Dublin
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	43017-3552
City Area Code	614
Local Phone Number	793-7500
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		30,359,792
Preferred Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Preferred Stock Purchase Rights
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock
Trading Symbol	NAVB
Security Exchange Name	NYSE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,217,114	$ 4,230,865
Receivables	115,845	92,992
Inventory	322,992	151,155
Prepaid expenses and other	667,439	908,273
Total current assets	2,323,390	5,383,285
Property and equipment	908,322	866,306
Less accumulated depreciation and amortization	756,385	745,816
Property and equipment, net	151,937	120,490
Right-of-use lease assets	448,940	448,940
Less accumulated amortization	351,078	320,725
Right-of-use lease assets, net	97,862	128,215
License agreements, patents and trademarks	981,825	953,424
Less accumulated amortization	180,081	167,773
License agreements, patents and trademarks, net	801,744	785,651
Other assets	227,192	227,192
Total assets	3,602,125	6,644,833
Current liabilities:
Accounts payable	1,564,933	1,421,317
Accrued liabilities and other	3,023,221	3,149,340
Notes payable	113,974	453,427
Lease liabilities, current	198,140	275,718
Total current liabilities	4,900,268	5,299,802
Lease liabilities, net of current portion	11,299	20,288
Deferred revenue	800,000	700,000
Total liabilities	5,711,567	6,020,090
Commitments and contingencies (See Note 10)
Stockholders’ (deficit) equity:
Common stock; $.001 par value, 300,000,000 shares authorized; 30,357,292 and 30,279,922 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively	221,354	221,277
Additional paid-in capital	371,151,466	370,459,705
Accumulated deficit	(373,774,852)	(370,787,610)
Total stockholders' deficit	(2,401,960)	(106,556)
Noncontrolling interest	292,518	731,299
Total Navidea stockholders’ (deficit) equity	(2,109,442)	624,743
Total liabilities and stockholders’ (deficit) equity	3,602,125	6,644,833
Non-Series Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	0	0
Series D Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	22	22
Series E Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	$ 50	$ 50

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	30,357,292	30,279,922
Common stock, shares outstanding (in shares)	30,357,292	30,279,922
Non-Series Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series D Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	150,000	150,000
Preferred stock, shares issued (in shares)	22,077	22,077
Preferred stock, shares outstanding (in shares)	22,077	22,077
Series E Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	50,000	50,000
Preferred stock, shares issued (in shares)	50,000	50,000
Preferred stock, shares outstanding (in shares)	50,000	50,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Revenue:
Revenue from contract with customer		$ 0	$ 22,486
Grant and other revenue		0	101,251
Total revenue		0	123,737
Cost of revenue		0	0
Gross profit		0	123,737
Operating expenses:
Research and development		1,169,254	1,222,754
Selling, general and administrative		1,810,030	2,230,745
Total operating expenses		2,979,284	3,453,499
Loss from operations	[1]	(2,979,284)	(3,329,762)
Other (expense) income:
Interest expense, net		(3,662)	(2,875)
Gain on extinguishment of debt		0	366,000
Other, net		(4,299)	(255)
Total other (expense) income, net		(7,961)	362,870
Net loss		(2,987,245)	(2,966,892)
Loss attributable to noncontrolling interest		3	2
Loss attributable to common stockholders		$ (2,987,242)	$ (2,966,890)
Loss attributable to common stockholders per common share (basic and diluted) (in dollars per share)		$ (0.10)	$ (0.11)
Weighted average shares outstanding (in shares)		30,207,746	28,066,296
License [Member]
Revenue:
Revenue from contract with customer		$ 0	$ 22,486
[1]	Income (loss) from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) - USD ($)	Director Fees [Member]Preferred Stock [Member]	Director Fees [Member]Common Stock [Member]	Director Fees [Member]Additional Paid-in Capital [Member]	Director Fees [Member]Retained Earnings [Member]	Director Fees [Member]Noncontrolling Interest [Member]	Director Fees [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2020								27,149,691
Balance at Dec. 31, 2020								$ 218,146	$ 375,428,014	$ (359,056,683)	$ 731,303	$ 2,046,907
Issued stock to 401(k) plan (in shares)								30,018				30,018
Issued stock to 401(k) plan								$ 30	76,816			$ 76,846
Stock compensation expense									121,298			121,298
Net loss										(2,966,890)	(2)	(2,966,892)
Balance (in shares) at Dec. 31, 2021								30,279,922
Balance at Dec. 31, 2021								$ 221,277	370,459,705	(370,787,610)	731,299	624,743
Issued stock in lieu of cash bonuses (in shares)							0	16,632
Issued stock in lieu of cash bonuses							$ 0	$ 17	16,948	0	0	$ 16,965
Issued stock to 401(k) plan (in shares)							0	53,238				53,238
Issued stock to 401(k) plan										0	0	$ 44,720
Issued stock in lieu of cash for payment of director fees (in shares)	0	7,500
Issued stock in lieu of cash for payment of director fees	$ 0	$ 7	$ 6,518	$ 0	$ 0	$ 6,525
MT Preferred Stock reacquired due to Platinum settlement							$ 0	$ 0	438,778	0	(438,778)	0
Stock compensation expense							0	0	184,850	0	0	184,850
Net loss							$ 0	$ 0	$ 0	$ (2,987,242)	$ (3)	$ (2,987,245)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Preferred Stock Subscription [Member]Series D Preferred Stock [Member]	Preferred Stock Subscription [Member]	Preferred Stock Subscriptions Receivable [Member]Series D Preferred Stock [Member]	Preferred Stock Subscriptions Receivable [Member]	Common Stock [Member]Series D Preferred Stock [Member]	Common Stock [Member]	Common Stock Subscription [Member]Series D Preferred Stock [Member]	Common Stock Subscription [Member]	Common Stock Subscriptions Receivable [Member]	Additional Paid-in Capital [Member]Series D Preferred Stock [Member]	Additional Paid-in Capital [Member]Series E Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Preferred Stock [Member]Series D Preferred Stock [Member]	Preferred Stock [Member]Series E Preferred Stock [Member]	Preferred Stock [Member]	Series D Preferred Stock [Member]	Series E Preferred Stock [Member]	Total
Balance (in shares) at Dec. 31, 2020		132,250				27,149,691		995,000
Balance at Dec. 31, 2020		$ 132		$ (10,300,000)		$ 218,146		$ 995	$ (4,975,000)			$ 375,428,014	$ (359,056,683)	$ 731,303						$ 2,046,907
Issued restricted stock (in shares)						12,500
Issued restricted stock						$ 13														$ 13
Issued stock to 401(k) plan (in shares)						30,018														30,018
Issued stock to 401(k) plan						$ 30						76,816								$ 76,846
Issued stock (in shares)	(31,750)														31,750	50,000
Issued stock	$ (31)		$ 250,000								$ 4,980,659				$ 32	$ 50		$ 250,001	$ 4,980,709
Issued stock upon conversion (in shares)					1,513,978		0								(31,750)
Issued stock upon conversion					$ 1,514					$ (1,482)					$ (32)
Stock subscribed (in shares)	0
Stock subscribed	$ 0		$ 500,000							$ 0								$ 500,000
Stock compensation expense												121,298								121,298
Net loss													(2,966,890)	(2)						(2,966,892)
Balance (in shares) at Mar. 31, 2021		100,500				28,706,187		995,000									50,000
Balance at Mar. 31, 2021		$ 101		$ (9,550,000)		$ 219,703		$ 995	$ (4,975,000)			380,605,305	(362,023,573)	731,301						5,008,882
Balance (in shares) at Dec. 31, 2021						30,279,922
Balance at Dec. 31, 2021						$ 221,277						370,459,705	(370,787,610)	731,299						$ 624,743
Issued stock to 401(k) plan (in shares)						53,238											0			53,238
Issued stock to 401(k) plan													0	0						$ 44,720
Stock compensation expense						$ 0						184,850	0	0			$ 0			184,850
Net loss						$ 0						0	(2,987,242)	(3)			$ 0			(2,987,245)
Balance (in shares) at Mar. 31, 2022						30,357,292											72,077
Balance at Mar. 31, 2022						$ 221,354						$ 371,151,466	$ (373,774,852)	$ 292,518						$ (2,109,442)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (2,987,245)	$ (2,966,892)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	22,878	17,748
Non-cash lease expense	30,354	30,378
Loss on abandonment of patent applications	47,774	0
Stock compensation expense	184,850	121,298
Gain on extinguishment of debt	0	(366,000)
Value of stock issued to 401(k) plan for employer matching contributions	44,720	76,846
Value of stock issued in payment of employee bonuses	16,965	0
Value of stock issued in payment of director fees	6,525	0
Changes in operating assets and liabilities:
Receivables	(22,852)	(21,414)
Inventory	(171,837)	3,556
Prepaid expenses and other assets	240,832	129,970
Accounts payable	143,616	72,403
Accrued and other liabilities	(149,083)	(106,135)
Lease liabilities	(86,567)	(77,256)
Deferred revenue	122,964	22,964
Net cash used in operating activities	(2,556,106)	(3,062,534)
Cash flows from investing activities:
Payments for purchases of equipment	(42,017)	0
Patent and trademark costs	(76,175)	(67,472)
Net cash used in investing activities	(118,192)	(67,472)
Cash flows from financing activities:
Proceeds from issuance of preferred stock, including stock subscriptions receivable	0	8,175,000
Proceeds from issuance of common stock	0	13
Principal payments on notes payable	(339,453)	(188,893)
Net cash (used in) provided by financing activities	(339,453)	7,966,830
Net (decrease) increase in cash and cash equivalents	(3,013,751)	4,836,824
Cash and cash equivalents, beginning of period	4,230,865	2,670,495
Cash and cash equivalents, end of period	1,217,114	7,507,319
Preferred Stock Issuance Costs [Member]
Cash flows from financing activities:
Payment of stock issuance costs	$ 0	$ (19,290)

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Summary of Significant Accounting Policies a. Basis of Presentation: March 31, 2022 three March 31, 2022 2021 March 31, 2022 not December 31, 2021, 10 March 28, 2022 ( “2021 10 Our consolidated financial statements include the accounts of Navidea and our wholly owned subsidiaries, Navidea Biopharmaceuticals Europe Limited (“Navidea Europe”) and Navidea Biopharmaceuticals Limited (“Navidea UK”), as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. b. Revenue Recognition: one We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development (“R&D”) costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3. c. Research and Development Costs: d. Inventory: first first 6. e. Intangible Assets: no three March 31, 2022 2021, three March 31, 2022 2021, f. Leases: 2018. 12 not 9. g. Contingent Liabilities: 450, Contingencies 10 10. h. Recently Adopted Accounting Standards: May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 2021 04 2021 04 2021 04 December 15, 2021, 2021 04 not In November 2021, No. 2021 10, Disclosures by Business Entities about Government Assistance 2021 10 2021 10 1 2 3 2021 10 December 15, 2021. 2021 10 1 2 2021 10 not

Note 2 - Liquidity

Note 2 - Liquidity	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Liquidity As disclosed in the notes to the consolidated financial statements included in the Company’s 2021 10 10. On April 10, 2022, two second first 16. We do not 19 19 NAV3 32 19 19 The current conflict between Ukraine and Russia has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may third may The Company has experienced recurring net losses and has used significant cash to fund its operations. The Company has considerable discretion over the extent of development project expenditures and has the ability to curtail the related cash flows as needed. The Company also continues working to establish new sources of funding, including potential equity investments, collaborations and additional grant funding that can augment the balance sheet. However, based on our current working capital and our projected cash burn, management believes that there is substantial doubt about the Company’s ability to continue as a going concern for a period of one 10

Note 3 - Revenue From Contracts

Note 3 - Revenue From Contracts With Customers	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3. Revenue from Contracts with Customers Navidea is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. We manage our business based on two Tc99m Tc99m one Tc99 The Company recognizes revenue from up-front license fees and pre-market milestones after the cash has been received from its customers and the performance obligations have been met. Payments for sales-based royalties and milestones are generally received after the related revenue has been recognized and invoiced. Normal payment terms generally range from 15 to 90 days following milestone achievement or royalty invoice, in accordance with each contract. Up-front and milestone payments received related to our license and distribution agreements in India and China are deferred until Tc99m Tc99m March 2022, not Tc99m not no not eight ten The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. Transaction prices do not third not When estimating a contract’s transaction price, the Company considers all the information (historical, current, and forecasted) that is reasonably available to it and identifies possible consideration amounts. Most of the Company’s contracts with customers include both fixed and variable components of the transaction price. Under those contracts, some or all of the consideration for satisfied performance obligations is contingent on events over which the Company has no Tc99m The milestone payments have a binary outcome (that is, the Company will either receive all or none not Royalties are estimated based on the expected value method because they are based on a variable amount of sales representing a range of possible outcomes. However, when taking into account the constraint on variable consideration, the estimate of future royalties included in the transaction price is generally $0. This conclusion is based on the fact that Tc99m not no no The Company also has an agreement in place to provide Meilleur Technologies, Inc. (“Meilleur”), a wholly-owned subsidiary of Cerveau Technologies, Inc. (“Cerveau”), worldwide rights to conduct research using NAV4694, NAV4694 The sublicense of NAV4694 No. 606, Revenue from Contracts with Customers 606” Up-front fees, milestones and royalties are generally non-refundable. Therefore, the Company does not During the three March 31, 2022 2021, three March 31, 2022 2021, not The following table disaggregates the Company’s revenue from contracts with customers for the three March 31, 2022 2021. Three Months Ended March 31, 2022 2021 License revenue: Tc99m tilmanocept - Europe $ — $ 22,486 The following economic factors affect the nature, amount, timing and uncertainty of the Company’s revenue and cash flows as indicated: Geographical Location of Customers: may may Tc99m Status of Regulatory Approval: Tc99m Tc99m Tc99m March 2022, not Tc99m not may NAV4694 not Through March 31, 2022, not The following table summarizes the changes in contract liabilities, the current portion of which is included in accrued liabilities and other in the consolidated balance sheets, during the three March 31, 2022 2021. Three Months Ended March 31, 2022 2021 Total deferred revenue, beginning of period $ 700,000 $ 700,000 Deferred revenue related to milestones achieved 100,000 — Total deferred revenue, end of period $ 800,000 $ 700,000 The Company had license revenue receivable of $100,000 and $1,021 outstanding as of March 31, 2022 December 31, 2021, In addition to revenue from contracts from customers, we also generate revenue from National Institutes of Health (“NIH”) grants to support various product development initiatives. The revenue recognition standard applies to revenue from contracts with customers. A customer is defined as a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ongoing major or central operations in exchange for consideration. The Company’s ongoing major or central operations consist of the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The NIH and its various institutes are responsible for biomedical and public health research and provide major biomedical research funding to non-NIH research facilities and entities such as Navidea. While the Company will directly benefit from any knowledge gained from the project, there is also a public health benefit provided, which justifies the use of public funds in the form of the grants. Based on the nature of the Company’s operations and the terms of the grant awards, Navidea does not not three March 31, 2022 2021,

Note 4 - Stock-based Compensati

Note 4 - Stock-based Compensation	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	4. Stock-Based Compensation For the three March 31, 2022 2021, not three March 31, 2022 2021. A summary of the status of our stock options as of March 31, 2022, three Three Months Ended March 31, 2022 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding, January 1, 2022 919,790 $ 5.67 6.5 $ — Granted 2,500 0.97 Cancelled/Forfeited (27,455 ) 6.29 Expired (6,185 ) 64.17 Outstanding, March 31, 2022 888,650 $ 5.23 6.3 $ — Exercisable, March 31, 2022 634,485 $ 6.73 5.1 $ — The weighted average grant date fair value per stock option granted during the three March 31, 2022 three March 31, 2022 A summary of the status of our unvested restricted stock as of March 31, 2022, three Three Months Ended March 31, 2022 Number of Shares Weighted Average Grant-Date Fair Value Unvested, January 1, 2022 95,000 $ 1.40 Vested (2,500 ) 2.28 Unvested, March 31, 2022 92,500 $ 1.38 As of March 31, 2022,

Note 5 - Loss Per Share

Note 5 - Loss Per Share	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	5. Loss Per Share Basic loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares. Diluted loss per share reflects additional common shares that would have been outstanding if dilutive potential common shares had been issued. Potential common shares that may Diluted loss per common share for the three March 31, 2022 2021 The Company’s unvested restricted stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested restricted stock awards are required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from continuing operations, 92,500 and 62,500 shares of unvested restricted stock for the three March 31, 2022 2021,

Note 6 - Inventory

Note 6 - Inventory	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	6. Inventory The components of inventory as of March 31, 2022 December 31, 2021 March 31, 2022 December 31. 2021 Materials $ 214,028 $ 50,000 Finished goods 108,964 101,155 Total inventory $ 322,992 $ 151,155 During the three March 31, 2021,

Note 7 - Accounts Payable, Accr

Note 7 - Accounts Payable, Accrued Liabilities and Other	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	7. Accounts Payable, Accrued Liabilities and Other Accounts payable as of March 31, 2022 December 31, 2021 March 31, 2022 December 31, 2021 March 31, 2022 December 31, 2021. July 1, 2022.

Note 8 - Notes Payable

Note 8 - Notes Payable	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	8. Notes Payable IPFS Corporation In November 2020, seven June 2021. November 2021, five April 2022. Interest expense related to the IPFS notes payable totaled $3,712 and $2,770 during the three March 31, 2022 2021, March 31, 2022,

Note 9 - Leases

Note 9 - Leases	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	9. Leases We currently lease approximately 5,000 square feet of office space at 4995 June 2023. In addition, we currently lease approximately 25,000 square feet of office space at 5600 2022. October 2022 five not June 2017, October 2022. We currently lease office equipment at a monthly payment of $136, expiring in October 2024. September 2021. Total operating lease expense was $37,676 and $45,832 for the three March 31, 2022 2021, The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of March 31, 2022. Maturity of Lease Liabilities Operating Lease Payments 2022 (remaining) $ 197,222 2023 19,699 2024 1,355 Total undiscounted operating lease payments 218,276 Less imputed interest 8,837 Present value of operating lease liabilities $ 209,439 Balance Sheet Classification Current lease liabilities $ 198,140 Noncurrent lease liabilities 11,299 Total operating lease liabilities $ 209,439 Other Information Weighted-average remaining lease term for operating leases (years) 0.8 Weighted-average discount rate for operating leases 10.9 % Cash paid for amounts included in the present value of operating lease liabilities was $93,889 and $92,711 during the three March 31, 2022 2021,

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	10. Commitments and Contingencies We are subject to legal proceedings and claims that arise in the ordinary course of business. The amount of ultimate liability, if any, with respect to these actions is unknown. CRG Litigation As disclosed in the notes to the financial statements included in the Company’s 2021 10 December 2017, March 3, 2017. March 2017, not June 2016 $66.0 $4.1 $4.1 $7.0 On April 9, 2018, 414, 414” $4.1 $59.0 The Company has also been engaged in ongoing litigation with CRG in the Court of Common Pleas of Franklin County, Ohio (the “Ohio Court”) related to Navidea’s claims that the CRG Lenders fraudulently induced Navidea to enter into a settlement agreement and breached the terms of the same through certain actions taken by the CRG Lenders in connection with the GSA, pursuant to which Navidea agreed to pay up to $66.0 $66.0 $4.1 June 2016 $66.0 $66.0 $7.1 414 May 7, 2019, June 28, 2019. November 27, 2019, $66.0 April 9, 2018, 414 no December 5, 2019, 10th March 27, 2020, September 23, 2020. March 16, 2021, 10th November 27, 2019 not not In April 2018, $7.1 not On November 21, 2021, not August 26, 2022. not Platinum Litigation In November 2017, March 3, 2017, October 31, 2018, no On November 30, 2018, January 22, 2019, September 5, 2019. November 25, 2019, not June 4, 2020, September 2, 2020, September 23, 2020 June 28, 2021. January 2022, 11. Goldberg Agreement and Litigation In August 2018, 1,175,000 November 2018, On February 11, 2019, February 19, 2019, March 1, 2019, February 20, 2019, may February 17, 2022, New York Litigation Involving Dr. Goldberg On February 20, 2019, April 26, 2019, June 13, 2019, third On December 26, 2019, third not The District Court also rejected Dr. Goldberg’s claim for wrongful termination as Chief Executive Officer of MT. In addition, the District Court found that Dr. Goldberg lacked standing to seek injunctive relief to force the removal of Dr. Claudine Bruck and Michael Rice from MT’s Board of Directors, to invalidate all actions taken by the MT Board on or after November 29, 2018 ( In addition, the District Court found Navidea’s breach of fiduciary duty claim against Dr. Goldberg for conduct occurring more than three On January 31, 2020, April 1, 2020, On January 27, 2020, July 9, 2020, 1 2 3 4 On August 24, 2020, not third not On May 27, 2021, 1 2 3 not 4 not third 5 6 not On August 6, 2021, June 23, 2021 ( October 14, 2021, March 7, 2022, September 1, 2020. April 8, 2022, September 1, 2020 March 31, 2022. May 19, 2022. Fact discovery and expert discovery in the New York Action have been completed. The Company has moved to disqualify Dr. Goldberg’s damages expert and briefing in the District Court was submitted on April 1, 2022. not Delaware Litigation Involving Dr. Goldberg On February 20, 2019, June 12, 2019, not May 23, 2019 On June 23, 2021, not not December 9, 2021, NYSE American Continued Listing Standards On January 28, 2022, not $6.0 1003 February 28, 2022 July 28, 2023. On April 8, 2022, not 1003 1003 $2.0 two three $4.0 three four December 31, 2021 five December 31, 2021. The NYSE American has granted the Company a plan period through July 28, 2023 1003 not not may

Note 11 - Equity

Note 11 - Equity	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Equity As discussed in Note 10, January 2022. six On January 31, 2022, March 2, 2021 ( six 16. During the three March 31, 2022 2021, 401 During the three March 31, 2022, 2021

Note 12 - Stock Warrants

Note 12 - Stock Warrants	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Stock Warrants Disclosure [Text Block]	12. Stock Warrants As of March 31, 2022,

Note 13 - Income Taxes

Note 13 - Income Taxes	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. Income Taxes Income taxes are accounted for under the asset and liability method in accordance with Accounting Standards Codification 740, Income Taxes Current accounting standards require a valuation allowance against DTAs if, based on the weight of available evidence, it is more likely than not may not March 31, 2022 December 31, 2021. In assessing the realizability of DTAs, management considers whether it is more likely than not not not not March 31, 2022. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no liability for uncertain tax positions was recorded as of March 31, 2022 December 31, 2021 not twelve March 31, 2022, 2018 2021 As of March 31, 2022, 2022 2037.

Note 14 - Segments

Note 14 - Segments	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	14. Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no inter-segment sales. We manage our business based on two Tc99m The information in the following tables is derived directly from each reportable segment’s financial reporting. Three Months Ended March 31, 2022 Diagnostics Therapeutics Corporate Total Research and development expenses $ 989,887 $ 179,367 $ — $ 1,169,254 Selling, general and administrative expenses, excluding depreciation and amortization (1) — — 1,787,152 1,787,152 Depreciation and amortization (2) 6,040 — 16,838 22,878 Loss from operations (3) (995,927 ) (179,367 ) (1,803,990 ) (2,979,284 ) Other expense (4) — — (7,961 ) (7,961 ) Net loss (995,927 ) (179,367 ) (1,811,951 ) (2,987,245 ) Total assets, net of depreciation and amortization: United States $ 150,920 $ — $ 3,034,316 $ 3,185,236 International 393,753 — 23,136 416,889 Capital expenditures 40,221 — 1,796 42,017 Three Months Ended March 31, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 22,486 $ — $ — $ 22,486 Grant and other revenue 101,251 — — 101,251 Total revenue 123,737 — — 123,737 Research and development expenses 1,094,390 128,364 — 1,222,754 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 2,006 2,210,991 2,212,997 Depreciation and amortization (2) 6,040 — 11,708 17,748 Loss from operations (3) (976,693 ) (130,370 ) (2,222,699 ) (3,329,762 ) Other income (4) — — 362,870 362,870 Net loss (976,693 ) (130,370 ) (1,859,829 ) (2,966,892 ) Total assets, net of depreciation and amortization: United States $ 160,669 $ — $ 9,723,212 $ 9,883,881 International 193,194 — — 193,194 Capital expenditures — — — — ( 1 General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not ( 2 Depreciation and amortization are reflected in selling, general and administrative expenses ($22,878 and $17,748 for the three March 31, 2022 2021, ( 3 Income (loss) from operations does not ( 4 Amounts consist primarily of gain on extinguishment of debt, interest income and interest expense, which are not

Note 15 - Supplemental Disclosu

Note 15 - Supplemental Disclosure for Statements of Cash Flows	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	15. Supplemental Disclosure for Statements of Cash Flows During the three March 31, 2022 2021, three March 31, 2021, 10 December 31, 2020 December 31, 2020. three March 31, 2022 2021, 401 three March 31, 2022, 2021

Note 16 - Subsequent Events

Note 16 - Subsequent Events	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	16. Subsequent Events The Company has evaluated events and transactions subsequent to March 31, 2022 10 Rights Agreement On April 7, 2022, 382 December 31, 2021, Under the Rights Agreement, the Board declared a non-taxable dividend of one preferred share purchase right for each outstanding share of common stock of the Company. The rights will be exercisable only if a person or group acquires 4.99% or more of Navidea common stock. Existing shareholders that beneficially own in excess of 4.99% may not The rights issued under the Rights Agreement will expire on the earliest of (i) April 6, 2025; ( 382 no first no may 2022 not Stock Exchange and Loan Agreement On April 10, 2022, two second first As consideration and a partial inducement for Mr. Scott to make the loan, at the closing, Mr. Scott agreed to deliver 50,000 shares of Series E Preferred Stock, representing 100% of the outstanding Series E Preferred Stock, to the Company in exchange for the Company’s issuance of 1,740 shares of Series F Redeemable Convertible Preferred Stock (“Series F Preferred Stock”) and 3,260 shares of Series G Redeemable Preferred Stock (“Series G Preferred Stock”). The number of shares of Common Stock that the Company may may not 33.33% April 12, 2022. In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement with Mr. Scott, pursuant to which the Company agreed to file a registration statement with the SEC to register the resale of the shares issuable to Mr. Scott upon conversion of the Series F Preferred Stock.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	a. Basis of Presentation: March 31, 2022 three March 31, 2022 2021 March 31, 2022 not December 31, 2021, 10 March 28, 2022 ( “2021 10 Our consolidated financial statements include the accounts of Navidea and our wholly owned subsidiaries, Navidea Biopharmaceuticals Europe Limited (“Navidea Europe”) and Navidea Biopharmaceuticals Limited (“Navidea UK”), as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation.
Revenue [Policy Text Block]	b. Revenue Recognition: one We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development (“R&D”) costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3.
Research and Development Expense, Policy [Policy Text Block]	c. Research and Development Costs:
Inventory, Policy [Policy Text Block]	d. Inventory: first first 6.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	e. Intangible Assets: no three March 31, 2022 2021, three March 31, 2022 2021,
Lessee, Leases [Policy Text Block]	f. Leases: 2018. 12 not 9.
Contingent Liability Reserve Estimate, Policy [Policy Text Block]	g. Contingent Liabilities: 450, Contingencies 10 10.
New Accounting Pronouncements, Policy [Policy Text Block]	h. Recently Adopted Accounting Standards: May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 2021 04 2021 04 2021 04 December 15, 2021, 2021 04 not In November 2021, No. 2021 10, Disclosures by Business Entities about Government Assistance 2021 10 2021 10 1 2 3 2021 10 December 15, 2021. 2021 10 1 2 2021 10 not

Note 3 - Revenue From Contrac_2

Note 3 - Revenue From Contracts With Customers (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, 2022 2021 License revenue: Tc99m tilmanocept - Europe $ — $ 22,486
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Three Months Ended March 31, 2022 2021 Total deferred revenue, beginning of period $ 700,000 $ 700,000 Deferred revenue related to milestones achieved 100,000 — Total deferred revenue, end of period $ 800,000 $ 700,000

Note 4 - Stock-based Compensa_2

Note 4 - Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Three Months Ended March 31, 2022 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding, January 1, 2022 919,790 $ 5.67 6.5 $ — Granted 2,500 0.97 Cancelled/Forfeited (27,455 ) 6.29 Expired (6,185 ) 64.17 Outstanding, March 31, 2022 888,650 $ 5.23 6.3 $ — Exercisable, March 31, 2022 634,485 $ 6.73 5.1 $ —
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Three Months Ended March 31, 2022 Number of Shares Weighted Average Grant-Date Fair Value Unvested, January 1, 2022 95,000 $ 1.40 Vested (2,500 ) 2.28 Unvested, March 31, 2022 92,500 $ 1.38

Note 6 - Inventory (Tables)

Note 6 - Inventory (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, 2022 December 31. 2021 Materials $ 214,028 $ 50,000 Finished goods 108,964 101,155 Total inventory $ 322,992 $ 151,155

Note 9 - Leases (Tables)

Note 9 - Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturity of Lease Liabilities Operating Lease Payments 2022 (remaining) $ 197,222 2023 19,699 2024 1,355 Total undiscounted operating lease payments 218,276 Less imputed interest 8,837 Present value of operating lease liabilities $ 209,439
Lessee, Operating Lease, Assets and Liabilities [Table Text Block]	Balance Sheet Classification Current lease liabilities $ 198,140 Noncurrent lease liabilities 11,299 Total operating lease liabilities $ 209,439
Lessee, Leases, Other Information [Table Text Block]	Other Information Weighted-average remaining lease term for operating leases (years) 0.8 Weighted-average discount rate for operating leases 10.9 %

Note 14 - Segments (Tables)

Note 14 - Segments (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended March 31, 2022 Diagnostics Therapeutics Corporate Total Research and development expenses $ 989,887 $ 179,367 $ — $ 1,169,254 Selling, general and administrative expenses, excluding depreciation and amortization (1) — — 1,787,152 1,787,152 Depreciation and amortization (2) 6,040 — 16,838 22,878 Loss from operations (3) (995,927 ) (179,367 ) (1,803,990 ) (2,979,284 ) Other expense (4) — — (7,961 ) (7,961 ) Net loss (995,927 ) (179,367 ) (1,811,951 ) (2,987,245 ) Total assets, net of depreciation and amortization: United States $ 150,920 $ — $ 3,034,316 $ 3,185,236 International 393,753 — 23,136 416,889 Capital expenditures 40,221 — 1,796 42,017 Three Months Ended March 31, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 22,486 $ — $ — $ 22,486 Grant and other revenue 101,251 — — 101,251 Total revenue 123,737 — — 123,737 Research and development expenses 1,094,390 128,364 — 1,222,754 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 2,006 2,210,991 2,212,997 Depreciation and amortization (2) 6,040 — 11,708 17,748 Loss from operations (3) (976,693 ) (130,370 ) (2,222,699 ) (3,329,762 ) Other income (4) — — 362,870 362,870 Net loss (976,693 ) (130,370 ) (1,859,829 ) (2,966,892 ) Total assets, net of depreciation and amortization: United States $ 160,669 $ — $ 9,723,212 $ 9,883,881 International 193,194 — — 193,194 Capital expenditures — — — —

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Patent and Trademark Costs	$ 76,175	$ 67,472
Previously Capitalized Patent Costs Abandoned	$ 47,774	$ 0
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	5 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	15 years

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - Purchase Agreement [Member] - Vice Chairman of Board of Directors [Member] - Subsequent Event [Member] - USD ($) $ in Millions	Apr. 12, 2022	Apr. 10, 2022
Debt Instrument, Face Amount		$ 2.5
Proceeds from Issuance of Long-Term Debt, Total	$ 1.5
Debt Instrument, Interest Rate, Stated Percentage		8.00%

Note 3 - Revenue From Contrac_3

Note 3 - Revenue From Contracts With Customers (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Contract with Customer, Payment Term, Minimum (Day)	15 days
Contract with Customer, Payment Term, Maximum (Day)	90 days
Contract with Customer, Transaction Price of Royalties Using Expected Value Method	$ 0
Revenue from Contract with Customer, Including Assessed Tax	0	$ 22,486
Contract with Customer, Asset, Impairment Loss	0	0
Contract with Customer, Asset, after Allowance for Credit Loss, Total	100,000		$ 1,021
Grant [Member]
Revenue Not from Contract with Customer	$ 0	$ 1,251
INDIA
Contract with Customer, Term of Contract (Year)	8 years
CHINA
Contract with Customer, Term of Contract (Year)	10 years

Note 3 - Revenue From Contrac_4

Note 3 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue from contract with customer	$ 0	$ 22,486
Diagnostics Segment [Member] | Royalty [Member] | Europe [Member]
Revenue from contract with customer	$ 0	$ 22,486

Note 3 - Revenue From Contrac_5

Note 3 - Revenue From Contracts With Customers - Changes in Contract Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Total deferred revenue, beginning of period	$ 700,000	$ 700,000
Deferred revenue related to milestones achieved	100,000	0
Total deferred revenue, end of period	$ 800,000	$ 700,000

Note 4 - Stock-based Compensa_3

Note 4 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-Based Payment Arrangement, Expense	$ 184,850	$ 121,298
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 0.77
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	99.92%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.69%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)	6 years 3 months
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 161,015
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	1 year 7 months 24 days

Note 4 - Stock-based Compensa_4

Note 4 - Stock-based Compensation - Summary of Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Outstanding at beginning of period (in shares) | shares	919,790
Outstanding at beginning of period, weighted average exercise price (in dollars per share) | $ / shares	$ 5.67
Granted (in shares) | shares	2,500
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 0.97
Cancelled/Forfeited (in shares) | shares	(27,455)
Cancelled/Forfeited, weighted average exercise price (in dollars per share) | $ / shares	$ 6.29
Expired (in shares) | shares	(6,185)
Expired, weighted average exercise price (in dollars per share) | $ / shares	$ 64.17
Outstanding at end of period (in shares) | shares	888,650
Outstanding at end of period, weighted average exercise price (in dollars per share) | $ / shares	$ 5.23
Outstanding, weighted average remaining contractual life (Year)	6 years 3 months 18 days
Exercisable at end of period (in shares) | shares	634,485
Exercisable at end of period, weighted average exercise price (in dollars per share) | $ / shares	$ 6.73
Exercisable, weighted average remaining contractual life (Year)	5 years 1 month 6 days

Note 4 - Stock-based Compensa_5

Note 4 - Stock-based Compensation - Summary of Unvested Restricted Stock (Details) - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Unvested at beginning of period (in shares) | shares	95,000
Unvested at beginning of period, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 1.40
Vested (in shares) | shares	(2,500)
Vested, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 2.28
Unvested at end of period (in shares) | shares	92,500
Unvested at end of period, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 1.38

Note 5 - Loss Per Share (Detail

Note 5 - Loss Per Share (Details Textual) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Stock Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1,310,974	1,751,794
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	92,500	62,500

Note 6 - Inventory (Details Tex

Note 6 - Inventory (Details Textual)	3 Months Ended
	Mar. 31, 2021USD ($)
Finished Goods [Member]
Inventory, Allocated to Research and Development Expense	$ 4,054

Note 6 - Inventory - Net Invent

Note 6 - Inventory - Net Inventory (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Materials	$ 214,028	$ 50,000
Finished goods	108,964	101,155
Total inventory	$ 322,992	$ 151,155

Note 7 - Accounts Payable, Ac_2

Note 7 - Accounts Payable, Accrued Liabilities and Other (Details Textual) - Director Fees [Member] - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Account Payable [Member]
Due to Related Parties, Current, Total	$ 119,182	$ 57,099
Accrued Liabilities and Other [Member]
Due to Related Parties, Current, Total	$ 948,752	$ 1,194,719

Note 8 - Notes Payable (Details

Note 8 - Notes Payable (Details Textual) - USD ($)	1 Months Ended		3 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Notes Payable, Current, Total			$ 113,974		$ 453,427
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | FIF [Member]
Debt Instrument, Face Amount	$ 565,760	$ 442,041
Debt Instrument, Interest Rate, Stated Percentage	4.36%	3.50%
Debt Instrument, Term (Month)	5 months	7 months
Debt Instrument, Periodic Payment, Total	$ 114,388	$ 63,888
Interest Expense, Debt, Total			3,712	$ 2,770
Notes Payable, Current, Total			$ 113,974

Note 9 - Leases (Details Textua

Note 9 - Leases (Details Textual)	1 Months Ended	3 Months Ended
	Jun. 30, 2017USD ($)	Mar. 31, 2022USD ($)ft²	Mar. 31, 2021USD ($)	Sep. 30, 2021ft²
Operating Lease, Expense		$ 37,676	$ 45,832
Operating Lease, Payments		93,889	$ 92,711
Office Space at 4995 Bradenton Avenue, Dublin Ohio [Member]
Area of Real Estate Property (Square Foot) | ft²				5,000
Operating Lease, Monthly Base Rent		$ 3,012
Office Space at 5600 Blazer Parkway, Dublin, Ohio [Member]
Area of Real Estate Property (Square Foot) | ft²		25,000
Operating Lease, Monthly Base Rent	$ 39,124	$ 28,149
Lessee, Operating Lease, Renewal Term (Year)		5 years
Office Equipment [Member]
Operating Lease, Monthly Base Rent		$ 136
Vehicle Lease [Member]
Operating Lease, Monthly Base Rent		$ 287

Note 9 - Leases - Maturity of L

Note 9 - Leases - Maturity of Lease Liabilities (Details)	Mar. 31, 2022USD ($)
2022 (remaining)	$ 197,222
2023	19,699
2024	1,355
Total undiscounted operating lease payments	218,276
Less imputed interest	8,837
Present value of operating lease liabilities	$ 209,439

Note 9 - Leases - Balance Sheet

Note 9 - Leases - Balance Sheet Classification (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current lease liabilities	$ 198,140	$ 275,718
Noncurrent lease liabilities	11,299	$ 20,288
Present value of operating lease liabilities	209,439
Other Current Liabilities [Member]
Current lease liabilities	198,140
Other Noncurrent Liabilities [Member]
Noncurrent lease liabilities	$ 11,299

Note 9 - Leases - Other Informa

Note 9 - Leases - Other Information (Details)	Mar. 31, 2022
Weighted-average remaining lease term for operating leases (years) (Year)	9 months 18 days
Weighted-average discount rate for operating leases	10.90%

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Details Textual) - USD ($)

Dec. 09, 2021

Nov. 21, 2021

May 27, 2021

Mar. 16, 2021

Nov. 27, 2019

Aug. 14, 2018

Apr. 09, 2018

Nov. 02, 2017

Mar. 03, 2017

Nov. 30, 2018

Apr. 30, 2018

Jun. 30, 2016

Mar. 31, 2022

Jan. 31, 2022

Dec. 31, 2021

Mar. 31, 2021

Dec. 31, 2020

Aug. 31, 2018

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance

$ (2,109,442)

$ 624,743

$ 5,008,882

$ 2,046,907

Common Stock [Member]

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance

221,354

$ 221,277

$ 219,703

$ 218,146

MT [Member]

Ownership Percentage

60.00%

Former Chief Executive Officer and President [Member]

Common Stock Shares Provided by Agreement (in shares)

1,175,000

Common Stock Shares Provided by Agreement, Escrow Period (Month)

18 months

Former Chief Executive Officer and President [Member] | Common Stock [Member]

Stock Issued During Period, Shares, New Issues (in shares)

925,000

Stock Issued During Period, Shares, New Issues Placed in Escrow (in shares)

250,000

Former Chief Executive Officer and President [Member] | MT [Member] | Common Stock [Member] | Dr. Michael Goldberg [Member]

Ownership Percentage

5.00%

CRG [Member]

Draws on Letter of Credit

$ 7,100,000

CRG Loan Agreement, Texas Case [Member]

Litigation Settlement, Attorneys’ Fees

$ 2,800,000

CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Loss Contingency, Damages Awarded, Value, Additional Amount

$ 7,000,000

Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration

$ 4,100,000

Ohio Court of Common Pleas [Member]

Litigation Settlement, Amount Awarded from Other Party

$ 4,300,000

Litigation Settlement, Reversal of Amount Awarded from Other Party

$ 4,300,000

Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 1,900,000

New York Litigation Involving Former CEO and President [Member] | Judicial Ruling [Member]

Litigation Settlement, Amount Can Be Awarded to Other Party for Indemnification for Attorneys’ Fees

$ 14,955

Litigation Settlement, Amount Can Be Advanced to Other Party for Attorneys’ Fees Subject to Repayment

$ 1,237.50

Litigation Settlement, Advancement for Attorney's Fees and Disbursements

$ 143,172.55

Delaware Litigation Involving Former CEO and President [Member]

Litigation Settlement, Amount Awarded from Other Party

$ 66,796.33

CRG [Member] | Term Loan Agreement [Member] | CRG Loan Agreement, Texas Case [Member]

Overpayment of Debt

$ 4,200,000

CRG [Member] | Term Loan Agreement [Member] | CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Repayments of Debt

59,000,000

CRG [Member] | Term Loan Agreement [Member] | Maximum [Member]

Debt Instrument, Agreed-upon Final Payoff Amount

$ 66,000,000

Note 11 - Equity (Details Textu

Note 11 - Equity (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jan. 31, 2022	Dec. 31, 2021
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance	$ 292,518			$ 731,299
Additional Paid in Capital, Total	$ 371,151,466			370,459,705
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)	53,238	30,018
Stock Issued During Period, Value, Employee Benefit Plan	$ 44,720	$ 76,846
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution	$ 44,720	$ 76,846
Common Stock [Member]
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)	53,238	30,018
Stock Issued During Period, Value, Employee Benefit Plan		$ 30
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)	16,632
Employees [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)	16,632
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution	$ 16,965
MT [Member]
Ownership Percentage			60.00%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance				$ 731,299
MT Preferred Stock [Member]
Preferred Stock, Stock Returned (in shares)			6
Additional Paid in Capital, Total			$ 438,779

Note 12 - Stock Warrants (Detai

Note 12 - Stock Warrants (Details Textual)	Mar. 31, 2022$ / sharesshares
Class of Warrant or Right, Outstanding (in shares) | shares	422,324
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2.30
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.20
Warrants and Rights Outstanding, Term (Year)	1 year 2 months 12 days
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 49.80
Warrants and Rights Outstanding, Term (Year)	13 years 4 months 24 days

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Unrecognized Tax Benefits, Ending Balance	$ 0	$ 0
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total	164,100	$ 164,000
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	9,100
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	$ 20,100

Note 14 - Segments (Details Tex

Note 14 - Segments (Details Textual)		3 Months Ended
		Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)
Revenues, Total		$ 0	$ 123,737
Number of Primary Types of Products Sold		2
Depreciation, Depletion and Amortization, Nonproduction, Total	[1]	$ 22,878	$ 17,748
Intersegment Eliminations [Member]
Revenues, Total		$ 0
[1]	Depreciation and amortization are reflected in selling, general and administrative expenses ($22,878 and $17,748 for the three-month periods ended March 31, 2022 and 2021, respectively).

Note 14 - Segments - Segment In

Note 14 - Segments - Segment Information (Details) - USD ($)		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Research and development expenses		$ 1,169,254	$ 1,222,754
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	1,787,152	2,212,997
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	22,878	17,748
Loss from operations	[3]	(2,979,284)	(3,329,762)
Other expense (4)	[4]	(7,961)	362,870
Net loss		(2,987,245)	(2,966,892)
Total assets, net of depreciation and amortization		3,602,125		$ 6,644,833
Capital expenditures		42,017	0
Revenue from contract with customer		0	22,486
Grant and other revenue		0	101,251
Revenues, Total		0	123,737
Research and development expenses		1,169,254	1,222,754
UNITED STATES
Total assets, net of depreciation and amortization		3,185,236	9,883,881
Non-US [Member]
Total assets, net of depreciation and amortization		416,889	193,194
License [Member]
Revenue from contract with customer		0	22,486
Diagnostics Segment [Member]
Research and development expenses		989,887	1,094,390
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	0	0
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	6,040	6,040
Loss from operations	[3]	(995,927)	(976,693)
Other expense (4)	[4]	0	0
Net loss		(995,927)	(976,693)
Capital expenditures		40,221	0
Grant and other revenue			101,251
Revenues, Total			123,737
Research and development expenses		989,887	1,094,390
Diagnostics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		150,920	160,669
Diagnostics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		393,753	193,194
Diagnostics Segment [Member] | License [Member]
Revenue from contract with customer			22,486
Therapeutics Segment [Member]
Research and development expenses		179,367	128,364
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	0	2,006
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	0	0
Loss from operations	[3]	(179,367)	(130,370)
Other expense (4)	[4]	0	0
Net loss		(179,367)	(130,370)
Capital expenditures		0	0
Grant and other revenue			0
Revenues, Total			0
Research and development expenses		179,367	128,364
Therapeutics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		0	0
Therapeutics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		0	0
Therapeutics Segment [Member] | License [Member]
Revenue from contract with customer			0
Corporate Segment [Member]
Research and development expenses		0	0
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	1,787,152	2,210,991
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	16,838	11,708
Loss from operations	[3]	(1,803,990)	(2,222,699)
Other expense (4)	[4]	(7,961)	362,870
Net loss		(1,811,951)	(1,859,829)
Capital expenditures		1,796	0
Grant and other revenue			0
Revenues, Total			0
Research and development expenses		0	0
Corporate Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		3,034,316	9,723,212
Corporate Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		$ 23,136	0
Corporate Segment [Member] | License [Member]
Revenue from contract with customer			$ 0
[1]	General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[2]	Depreciation and amortization are reflected in selling, general and administrative expenses ($22,878 and $17,748 for the three-month periods ended March 31, 2022 and 2021, respectively).
[3]	Income (loss) from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[4]	Amounts consist primarily of gain on extinguishment of debt, interest income and interest expense, which are not currently allocated to our individual reportable segments.

Note 15 - Supplemental Disclo_2

Note 15 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Interest Paid, Excluding Capitalized Interest, Operating Activities	$ 3,712	$ 2,900
Proceeds from Issuance of Preferred Stock and Preference Stock	$ 0	$ 8,175,000
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)	53,238	30,018
Stock Issued During Period, Value, Employee Benefit Plan	$ 44,720	$ 76,846
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution	$ 44,720	$ 76,846
Common Stock [Member]
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)	53,238	30,018
Stock Issued During Period, Value, Employee Benefit Plan		$ 30
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)	16,632
Employees [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)	16,632
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution	$ 16,965
Series D Preferred Stock [Member] | Keystone Capital Partners, LLC [Member]
Proceeds from Issuance of Preferred Stock and Preference Stock		$ 2.925

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual) - USD ($) $ in Millions	Apr. 12, 2022	Apr. 10, 2022	Apr. 07, 2022	Mar. 31, 2022	Dec. 31, 2021
Subsequent Event [Member] | Conversion of Series E Preferred Stock to Series F Preferred Stock and Series G Preferred Stock [Member]
Conversion of Stock, Shares Converted (in shares)	50,000
Percentage of Outstanding Preferred Stock	100.00%
Subsequent Event [Member] | Conversion of Series E Preferred Stock to Series F Preferred Stock and Series G Preferred Stock [Member] | Series F Preferred Stock [Member]
Conversion of Stock, Shares Issued (in shares)	1,740
Subsequent Event [Member] | Conversion of Series E Preferred Stock to Series F Preferred Stock and Series G Preferred Stock [Member] | Series G Preferred Stock [Member]
Conversion of Stock, Shares Issued (in shares)	3,260
Subsequent Event [Member] | Vice Chairman of Board of Directors [Member]
Percentage of Common Stock, Cap	33.33%
Subsequent Event [Member] | Purchase Agreement [Member] | Vice Chairman of Board of Directors [Member]
Debt Instrument, Face Amount		$ 2.5
Proceeds from Issuance of Long-Term Debt, Total	$ 1.5
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Preferred Stock Purchase Rights Agreement [Member] | Subsequent Event [Member]
Non-taxable Dividend, Preferred Share Purchase Right Per Outstanding Common Stock (in shares)			1
Minimum Percentage of Common Stock			4.99%
Additional Percentage of Common Stock Acquired			0.50%
Percentage of Discount Entitled in Purchasing Common Stock			50.00%
Class of Right, Common Stock Shares Converted (in shares)			5
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total				$ 164.1	$ 164